A retrospective cohort study to determine efficacy of Ustekinumab in patients with active perianal Crohn's disease in a real-world Danish setting
Latest Information Update: 02 Dec 2020
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 02 Dec 2020 New trial record
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week